Abstract:Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45 + cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.

The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma

Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Cannabinoids in the treatment of glioblastoma

Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy

The immunosuppressive microenvironment and immunotherapy in human glioblastoma

The application of cannabidiol in the treatment of glioblastoma

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Molecular Mechanisms Involved in Angiogenesis and Potential Target of Antiangiogenesis in Human Glioblastomas

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Targeting Innate Immunity in Glioma Therapy

Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

GABAergic signaling as a potential therapeutic target in cancers

Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma

GABAergic signaling beyond synapses: an emerging target for cancer therapy

Advances in blood–brain barrier-crossing nanomedicine for anti-glioma

Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds

The Advances in Targeted Therapy and Immunotherapy for Glioblastoma: Basic Research and Clinical Trials

Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy